Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors

#96

Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.

Aim(s): We investigated mTOR, 4EBP1, pospho-4EBP1 expression in gastrointestinalpancreatic NETs, to disclose their role in this tumor sort.

Materials and methods: Ninety-nine cases of well-differentiated NETs from foregut (47, 47.5%) and midgut (52, 52.5%) were included in this study. Immunohistochemical expression of mTOR and total as well as phosphorylated 4EBP4 were investigated in specimen of NETs. Expression patterns were correlated with clinicopathologic variables and patient prognosis.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Atsuko K

Authors: Kasajima A, Pavel M, Darb-Esfahani S, Stenzinger A, Sasano H,

Keywords: neuroendocrine tumor, proliferation index ,

To read the full abstract, please log into your ENETS Member account.